Far from being over, the struggle to control infectious diseases has become an increasingly difficult problem, and controlling infectious diseases is an imperative global challenge that requires a global response. Canada must continue to recognize its global responsibility, and the Government of Canada must continue to provide the necessary funding to basic research which will allow Canadian scientists to contribute to this global response. This represents a major accomplishment and more clearly defines the role of the NCEs as Phase III commences. With 57 Principal Investigators working in 15 Universities and 3 Government laboratories, CBDN has a wealth of new approaches for diagnosing, preventing and treating bacterial diseases. Please find following, a listing of some CBDN research projects that we have chosen to highlight this quarter.
Patent applications are pending.
Patent protection has been sought. At present, there are no vaccines available against P. aeruginosa and antibiotic therapy is not completely effective in resolving this infection in persons that are immunocompromised or those who suffer from Cystic Fibrosis. This technology represents the first efficacious peptide-based vaccine against a human bacterial pathogen. We would like to take this opportunity to officially welcome the following CBDN Members, each of whom has become a part of our network within the last year. By highlighting their areas of expertise, we also hope to facilitate an even greater level of networking' with Industry Partners and other CBDN Scientists.